Why Is There an Estrogen Patch Shortage in Australia?
By Johanna Wicks & Raisa Monteiro, Co-founders, LORAI Health | May 2026
If you have tried to fill a prescription for an estrogen patch in Australia recently, you already know something is wrong. Dispensing pharmacists are calling around to find stock. Women are travelling between suburbs trying to locate their medication. The Therapeutic Goods Administration (TGA) has maintained an active shortage notice since 2023 and has now extended it to February 2027.
The explanation that has circulated most widely, that the shortage is caused by a lack of raw ingredients such as soya beans and sweet potatoes, is not accurate. The real cause runs deeper, and understanding it matters if you want to know when this shortage is likely to resolve. Short answer: not soon.
This article explains what is actually driving Australia's ongoing estrogen patch shortage, why the structure of global MHT patch manufacturing makes it so difficult to fix quickly, and what a credible long-term solution looks like.
What Is Causing the Estrogen Patch Shortage in Australia?
The estrogen patch shortage in Australia is not a raw ingredient problem. It is a manufacturing capacity problem, the result of decades of underinvestment in women's health infrastructure colliding with a sharp, long-overdue rise in demand for menopause hormone therapy (MHT).
Three forces have converged to create the current situation:
Global manufacturing capacity for estradiol patches is structurally insufficient to meet current demand
A major pharmaceutical company withdrew their patch from the market in late 2023, removing significant supply precisely as demand was accelerating
A landmark US regulatory change in late 2025 triggered a further surge in prescriptions worldwide
Each of these deserves careful examination.
Is Estradiol Actually in Short Supply Globally?
The raw materials used to synthesise estradiol, plant-derived sterols from soya beans and wild yam, are not the problem. The global pharmaceutical-grade estradiol supply chain, while not without its complexities, is not the reason Australian women cannot fill their prescriptions.
The constraint is manufacturing capacity for the finished transdermal patch product itself. Making an estradiol patch is a precision process: the hormone must be suspended in a polymer matrix at the correct concentration, layered onto a backing, cut to exact tolerances, and packaged under controlled conditions. The facilities capable of doing this at a pharmaceutical scale are few, highly regulated, and critically already operating at full capacity.
The US Department of Health and Human Services has publicly confirmed that all five US estradiol patch manufacturers are currently running at full capacity. Australia and New Zealand, which have no domestic manufacturing capability of their own, are entirely dependent on whatever these facilities can export after meeting their primary markets.
Why Australia Struggles to Secure Estrogen Patch Supply
Australia's exposure to the MHT patch shortage is acute for a straightforward reason: there is no domestic manufacturing backstop. All estradiol patches used in Australia are imported, and the supply chain for those imports currently depends on no more than two offshore facilities.
Facility One: Noven, Miami (Estradot and related brands)
Noven's plant in Miami manufactures for Sandoz globally, which includes Estradot, the estradiol-only patch most commonly prescribed in Australia. Noven has stated it is fulfilling all orders, while acknowledging that "supply challenges are possible" as demand rises. Sandoz, entirely dependent on Noven for supply, has confirmed that "unprecedented demand cannot be fully met at present." Multiple estradiol patch products are formally listed in shortage by the American Society of Health-System Pharmacists.
Facility Two: LTS Lohmann, Germany (Estraderm MX)
LTS Lohmann's facility in Germany manufactures patches for the Estraderm MX brands sold in Australia through a multi-party Novartis → Norgine → Juno Pharmaceuticals licensing chain. This is the second of only two supply pathways into the Australian market.
Two facilities supplying an entire country. Both under strain. No domestic manufacturing alternative.
The Role of Global Manufacturing Bottlenecks: How Did We Get Here?
Until late 2023, the global supply picture was modestly more resilient. There were three supply pathways: the Noven/Sandoz network, Bayer's Climara® patch (manufactured by Kindeva in California), and Juno's Estraderm MX from LTS Lohmann in Germany.
Bayer's Commercial Exit
In late 2023, Bayer made a commercial decision to discontinue Climara® globally. In February 2026, they discontinued the equivalent UK product, Progynova® TS. Two estradiol-only patch products were removed from the market within 26 months, not because manufacturing capability disappeared, but because Bayer determined these products no longer aligned with their commercial portfolio strategy.
That Kindeva facility in California remains fully intact and capable of production. The equipment has not been decommissioned. Bayer made a deliberate commercial choice to cease manufacturing estrogen patches there. That decision, defensible from a portfolio management standpoint, removed significant global supply precisely as demand was beginning to surge.
The FDA Black Box Removal: Demand Accelerated Further
In November 2025, the FDA removed the black box warning from bioidentical estradiol patches. That warning had been applied to all hormone therapy products since the 2002 Women's Health Initiative (WHI) study, a study that has since been substantially reanalysed, and whose conclusions about estradiol patches were always contested by specialists.
That warning had a profound effect on clinical practice for more than twenty years, driving systematic under-prescribing of hormone therapy and leaving millions of women without treatment that evidence now supports. Its removal sent a clear signal to clinicians and patients: this is safe. Prescriptions accelerated sharply. Manufacturers, already at capacity, had no ability to respond in the short term.
The Legacy of the WHI Study and Demand Forecasting
To understand why supply was so poorly positioned to meet rising demand, you have to understand what the 2002 WHI study did to MHT prescribing for twenty years.
The study generated headlines suggesting that hormone therapy caused breast cancer and heart disease. Prescriptions collapsed. Manufacturers reduced investment accordingly. The pharmaceutical industry, like any industry, allocates capital where demand exists, and for two decades, the signal was that demand for MHT would remain suppressed.
The reanalysis of that data, showing that the risks applied primarily to synthetic progestins, not to transdermal estradiol, gradually shifted medical consensus. But the manufacturing base did not rebuild in parallel. The result is a system that is now trying to supply a market whose demand has recovered far faster than its production capacity.
This is not a short-term supply hiccup. It is the predictable consequence of two decades of underinvestment, triggered by flawed science that suppressed legitimate medical demand and the capital investment that would have followed it.
Why the Menopause Patch Shortage Keeps Happening
The deeper issue is structural. Australia's pharmaceutical supply security depends almost entirely on the commercial decisions of offshore manufacturers who serve primarily the US and European markets. Australia is, in commercial terms, a small and geographically inconvenient customer.
When global demand rises, or when a manufacturer decides a product line is no longer commercially attractive, Australia and New Zealand simply receive what is left. The TGA shortage register is a record of that dependency, updated regularly.
Consider the precedent set by Estrogel. The only way Besins Healthcare resolved its significant supply shortages in Europe and the UK in 2021–2022 was by building an entirely new manufacturing facility in Muel, Spain. Ramping up existing production did not solve it. Only the new capacity did.
There are currently no publicly disclosed plans for any new large-scale estradiol patch manufacturing facility globally. Noven's only confirmed capital investment is a quality control laboratory, which enables faster batch release but adds no manufacturing lines. Building a new pharmaceutical facility from decision to commercial output takes three to five years under optimal conditions.
The supply constraint is not going to self-correct quickly.
What Women Can Do Right Now
While the structural problem requires a structural solution, there are practical steps women can take to manage the current shortage:
Speak to your GP or menopause specialist about clinically equivalent alternatives. Estradiol gel, and oral options may be appropriate depending on your clinical profile
Ask your pharmacist to check multiple suppliers and wholesalers; availability varies by location and week
If you are prescribed Estradot or Estraderm MX specifically, ask whether the other brand is currently available in your area
Do not stop MHT abruptly without medical guidance. Work with your prescriber on a managed transition if your usual product is unavailable
Stay informed. Supply availability changes. LORAI Health tracks TGA notices and supply updates. Sign up below to receive updates as they happen.
What women should not have to do is navigate this alone, repeatedly, for a medicine that is neither new nor niche.
What Needs to Change: The Case for Sovereign Manufacturing Capability
Australia has spent three decades quietly dismantling its domestic pharmaceutical manufacturing capability, offshoring production on the logic of cheaper global supply chains. For a long time, it worked. COVID-19 exposed the first major crack. The estrogen patch shortage is the same lesson playing out more slowly, with less political urgency, because it affects women in midlife, a group historically under-served by health policy.
This is not a niche problem. Menopause is a universal biological reality for women, it is not a condition that affects a minority, it is a phase of life that reaches the entire female population. The Oceania region is currently almost entirely dependent on two facilities in Miami and Germany, neither of which was established with this region as a priority market. That is not a resilient foundation for healthcare in the 21st century.
A credible long-term solution requires investment in sovereign manufacturing capability, a vertically integrated facility designed to serve Australia, New Zealand, and the Asia-Pacific, that is not subject to the commercial portfolio decisions of offshore pharmaceutical multinationals.
Australia has the regulatory framework, the scientific capability, and a patient population that is, frankly, furious. What has been absent is a commitment equal to the scale of the problem.
Stay Informed on Supply Updates
We track TGA shortage notices, global manufacturing developments, and policy changes affecting menopause hormone therapy supply in Australia.
Sign up to our newsletter to receive updates and to follow LORAI Health's progress in building the manufacturing solution this country needs.
This article builds on analysis originally published by Johanna Wicks on Substack (May 2026). It has been substantially expanded and reworked as an evergreen explainer for LORAI Health.
This analysis draws on publicly available information and industry sources. Manufacturing structures and supply arrangements may not be fully disclosed and may evolve over time.